1073354-51-4Relevant articles and documents
Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial in Vitro and in Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus
Rehberg, Nidja,Sommer, Gereon A.,Drie?en, Daniel,Kruppa, Marco,Adeniyi, Emmanuel T.,Chen, Shang,Wang, Lin,Wolf, Karina,Tasch, Boris O. A.,Ioerger, Thomas R.,Zhu, Kui,Müller, Thomas J. J.,Kalscheuer, Rainer
, p. 12623 - 12641 (2020)
Natural bisindole alkaloids such as Hyrtinadine A and Alocasin A, which are known to exhibit diverse bioactivities, provide promising chemical scaffolds for drug development. By optimizing the Masuda borylation-Suzuki coupling sequence, a library of various natural product-derived and non-natural (di)azine-bridged bisindoles was created. While unsubstituted bisindoles were devoid of antibacterial activity, 5,5′-chloro derivatives were highly active against methicillin-resistant Staphylococcus aureus (MRSA) and further Gram-positive pathogens at minimal inhibitory concentrations ranging from 0.20 to 0.78 μM. These compounds showed strong bactericidal killing effects but only moderate cytotoxicity against human cell lines. Furthermore, the two front-runner compounds 4j and 4n exhibited potent in vivo efficacy against MRSA in a mouse wound infection model. Although structurally related bisindoles were reported to specifically target pyruvate kinase in MRSA, antibacterial activity of 4j and 4n is independent of pyruvate kinase. Rather, these compounds lead to bacterial membrane permeabilization and cellular efflux of low-molecular-weight molecules.
Pyrimidine derivatives Anaplastic lymphoma kinase inhibitors
-
, (2017/07/23)
The invention belongs to the field of a medical technology and specifically relates to a pyrimidine derivative type anaplastic lymphoma kinase inhibitor as shown in the general formula (I) or its stereisomer, or its pharmaceutically acceptable salt, ester or solvate, wherein R1, R2, R3, R4, R5 and A ring are as defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutic preparation and a pharmaceutical composition containing the compounds and an application of the compound or its stereisomer, or its pharmaceutically acceptable salt, ester or solvate in the preparation of medicines for treating and/or preventing diseases related to anaplastic lymphoma kinase-mediated cancer.